Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered question first ministerially corrected answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

532946

registered interest
date	05/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sexually Transmitted Infections
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will direct Public Health England to commission research into the inequality of the distribution of sexually transmitted infections between young people and the rest of the population.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	41881
answer	answer is ministerial correction date of answer 12/07/2016 answer text <p>The Department’s National Institute for Health Research funds the Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections. This is a research partnership between University College London and Public Health England, in collaboration with the London School of Hygiene and Tropical Medicine. The unit has a programme of research looking at reducing risk of sexually transmitted infections among important risk groups, and at reducing inequalities and improving sexual health.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/07/2016 09:11:44 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

523972

registered interest
date	08/06/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Chemotherapy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate NHS England has made of the projected savings from the introduction of dose banding of chemotherapy drugs without affecting quality of care.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	40000
answer	answer is ministerial correction date of answer 14/06/2016 answer text <p>NHS England has advised that the dose banding initiative forms part of its Specialised Commissioning Improving Value programme and can be considered as an expansion of current practice and direction of travel. The dose banding scheme has been primarily designed to deliver improvements in safety and quality of care.</p><p>NHS England advises that the scheme does also have the potential to deliver efficiencies for hospitals and its initial estimate is that this could release up to £5 million of value to the health system.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/06/2016 15:56:22 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

522125

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what compliance procedures the Medicines and Healthcare Products Regulatory Agency has to ensure that its pharmacovigilance functions do not conflict with the relationships it builds with private companies when seeking business from such companies.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38832
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>The requirements for the pharmacovigilance functions of the Medicines and Healthcare products Regulatory Agency (MHRA) are set out in European legislation through Directive 2010/84/EU and Regulation (EU) No 1235/2010 and in the Human Medicines Regulations 2012. MHRA is required to carry out independent audits of these pharmacovigilance functions and report to the European Commission every two years. This is in addition to routine reporting to the Commission on Human Medicines.</p><p>The requirements on private companies in the pharmaceutical industry that hold Marketing Authorisations for medicinal products are also set out in the same legislation and the MHRA carry out inspections to ensure these companies are compliant with the requirements. The MHRA has contact with pharmaceutical companies in its day to day business as necessary to fulfil the requirements of its pharmacovigilance functions.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 11:19:19 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

522126

registered interest
date	26/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the Medicines and Healthcare Products Regulatory Agency holds any clinical trial data for HPV vaccines which is not in the public domain.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38833
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>There are <del class="ministerial">two</del> <ins class="ministerial">three </ins>human papilloma virus vaccines licensed in the European Union: Cervarix<ins class="ministerial">,</ins> <del class="ministerial">and</del> <ins class="ministerial">Gardasil and </ins>Gardasil 9. These products are licensed centrally throughout Europe by the European Commission via the European Medicines Agency (EMA). Applicants for centrally authorised products are required to submit all relevant supporting clinical trials data, whether published or not, to the EMA directly and not to the Medicines and Healthcare products Regulatory Agency.</p><p> </p><p>Under current medicines legislation, the EMA database registers all EU-approved clinical trials of investigational medicinal products. Since March 2011 this information has been publicly accessible through the EU Clinical Trials Register (except adult Phase 1 trials). The EU Clinical Trials Register includes all EU-conducted trials since May 2004 when the Clinical Trials Directive was implemented and can be found here:</p><p> </p><p><a href="https://www.clinicaltrialsregister.eu/ctr-search/search" target="_blank">https://www.clinicaltrialsregister.eu/ctr-search/search</a></p><p> </p><p>Furthermore since July 2014 clinical trial sponsors have been required to provide a summary of their trial results uploaded onto the EU Clinical Trials Register within one year of their trial completing. There is a two year programme of back-loading underway to provide summaries of trial results for all trials on the Register back to when the EudraCT database was initiated in May 2004.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 10:57:37 question first ministerially corrected 13/06/2016 10:14:27 answering member 4020 label Biography information for George Freeman previous answer version 2228 answering member constituency Mid Norfolk answering member printed George Freeman answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

521611

registered interest
date	25/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Urine Drainage Bags
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions his Department has had with NHS Supply Chain on that organisation's decision on the choice of urine drainage bags available through the NHS Core List Programme.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38552
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>The NHS Supply Chain Core List Programme was developed in collaboration with NHS Business Services Authority and the Department. The Core List aims to achieve best value by reducing the range of like-for-like products that the National Health Service purchases. This allows the NHS to commit to larger volumes of a smaller range of products which in turn allows suppliers to provide improved prices to the NHS as greater economies of scale in manufacturing can be achieved.</p><p> </p><p>Items identified as ‘Core List’ have been reviewed and assessed by a selection of industry specialists, clinical advisors and customers. Products not included in the NHS Core List are not discontinued and are therefore still available for purchase via the wider NHS catalogue offered by NHS Supply Chain.</p><p> </p><p>Ultimately, decisions with regard to which urine drainage bag to purchase lies with the procurement team for each individual NHS trust.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 11:26:52 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

521614

registered interest
date	25/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Department of Health: Procurement
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department has assessed the effect on (a) patients and (b) patient choice of centralised procurement.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38573
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>‘Centralised procurement’ can sometimes be used to refer to the services of NHS Supply Chain. NHS Supply Chain offers a procurement and logistics service to all National Health Service trusts in the United Kingdom under a central service contract on behalf of NHS Business Services Authority.</p><p>There is currently no centralised procurement model mandated to the NHS by the Department, and as such no assessment has been made as to an effect on patients or patient choice. NHS trusts may choose to utilise the service offering of NHS Supply Chain, or choose an alternative. It is for NHS trusts to make their own choices with regard to products and services they purchase; therefore it is for individual trusts to assess any impact on patients and patient choice.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/06/2016 11:27:59 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

521264

registered interest
date	24/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent guidance his Department published to commissioners on meeting excess treatment costs for clinical trials.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38126
answer	answer is ministerial correction date of answer 27/05/2016 answer text <p>In November 2015, NHS England published new guidance to help clarify the rules and expectations on the funding of excess treatment costs incurred during a non-commercial research study. The guidance is provided for clinical commissioning groups and commissioners of specialised services.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/05/2016 11:25:56 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

521267

registered interest
date	24/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what methodology and data NHS England plans to use to determine which services it will commission at the specialised commissioning prioritisation process in June 2016.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38129
answer	answer is ministerial correction date of answer 27/05/2016 answer text <p>The Clinical Priorities Advisory Group (CPAG) will agree recommendations as to which proposals for new investments in specialised services should be considered by NHS England in the prioritisation round for 2016/17. CPAG is scheduled to meet between 6 and 9 June 2016.</p><p> </p><p>NHS England is currently considering the outcome of a public consultation that it held between April and May 2016 on a proposed method for the relative prioritisation of new investments in specialised services. The consultation guide that it published described the proposed method and the types of data that would be considered. Many detailed submissions were made by respondents to consultation, and they will all be carefully considered. NHS England is expecting to make a decision on the eventual method that will be adopted for 2016/17 in May 2016.</p><p> </p><p>The consultation guide can be found at the following address:</p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/investment-decisions/supporting_documents/consultationguide.pdf" target="_blank">https://www.engage.england.nhs.uk/consultation/investment-decisions/supporting_documents/consultationguide.pdf</a></p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 38130 question first answered 27/05/2016 11:33:00 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

521268

registered interest
date	24/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many services which have been approved by NHS England's Clinical Priorities Advisory Group are planned for discussion at the NHS England prioritisation round in June.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38130
answer	answer is ministerial correction date of answer 27/05/2016 answer text <p>The Clinical Priorities Advisory Group (CPAG) will agree recommendations as to which proposals for new investments in specialised services should be considered by NHS England in the prioritisation round for 2016/17. CPAG is scheduled to meet between 6 and 9 June 2016.</p><p> </p><p>NHS England is currently considering the outcome of a public consultation that it held between April and May 2016 on a proposed method for the relative prioritisation of new investments in specialised services. The consultation guide that it published described the proposed method and the types of data that would be considered. Many detailed submissions were made by respondents to consultation, and they will all be carefully considered. NHS England is expecting to make a decision on the eventual method that will be adopted for 2016/17 in May 2016.</p><p> </p><p>The consultation guide can be found at the following address:</p><p> </p><p><a href="https://www.engage.england.nhs.uk/consultation/investment-decisions/supporting_documents/consultationguide.pdf" target="_blank">https://www.engage.england.nhs.uk/consultation/investment-decisions/supporting_documents/consultationguide.pdf</a></p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 38129 question first answered 27/05/2016 11:33:00 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

519256

registered interest
date	18/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what legal costs (a) his Department and (b) NHS England have incurred to date in relation to decisions on access to (i) narcolepsy drugs, (ii) hepatitis C drugs and (iii) pre-exposure prophylaxis for HIV.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	37421
answer	answer is ministerial correction date of answer 25/05/2016 answer text <p>The Department’s legal costs are met from individual teams’ existing legal budgets and cannot be broken down further. NHS England also advises that it is not able to provide this information as these are live issues incurring ongoing legal costs.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/05/2016 14:07:11 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne